Similarly, NCAPH can be used as a prognostic biomarker for non-small cell lung cancer, lung adenocarcinoma, nasopharyngeal carcinoma, breast cancer, and hepatocellular carcinoma [22–26]. This evidence concerns the gene NCAPH and hepatocellular carcinoma.